IL212285A0 - Azaindole derivatives - Google Patents

Azaindole derivatives

Info

Publication number
IL212285A0
IL212285A0 IL212285A IL21228511A IL212285A0 IL 212285 A0 IL212285 A0 IL 212285A0 IL 212285 A IL212285 A IL 212285A IL 21228511 A IL21228511 A IL 21228511A IL 212285 A0 IL212285 A0 IL 212285A0
Authority
IL
Israel
Prior art keywords
azaindole derivatives
azaindole
derivatives
Prior art date
Application number
IL212285A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of IL212285A0 publication Critical patent/IL212285A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL212285A 2008-10-23 2011-04-12 Azaindole derivatives IL212285A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008052943A DE102008052943A1 (de) 2008-10-23 2008-10-23 Azaindolderivate
PCT/EP2009/006911 WO2010046013A1 (de) 2008-10-23 2009-09-24 Azaindolderivate

Publications (1)

Publication Number Publication Date
IL212285A0 true IL212285A0 (en) 2011-06-30

Family

ID=41268294

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212285A IL212285A0 (en) 2008-10-23 2011-04-12 Azaindole derivatives

Country Status (9)

Country Link
US (1) US20110207732A1 (cg-RX-API-DMAC7.html)
EP (1) EP2342202B1 (cg-RX-API-DMAC7.html)
JP (1) JP5662325B2 (cg-RX-API-DMAC7.html)
AU (1) AU2009306795B2 (cg-RX-API-DMAC7.html)
CA (1) CA2741428C (cg-RX-API-DMAC7.html)
DE (1) DE102008052943A1 (cg-RX-API-DMAC7.html)
ES (1) ES2559427T3 (cg-RX-API-DMAC7.html)
IL (1) IL212285A0 (cg-RX-API-DMAC7.html)
WO (1) WO2010046013A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5596364B2 (ja) * 2009-02-19 2014-09-24 住友化学株式会社 含窒素有機化合物及びそれを用いた有機エレクトロルミネッセンス素子
WO2011075613A1 (en) * 2009-12-18 2011-06-23 Sanofi Azaindole derivatives, their preparation and their therapeutic application
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
CA2834049C (en) 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
EA031618B1 (ru) * 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Соединения-модуляторы gpr-119
GB201217285D0 (en) * 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP6320506B2 (ja) * 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
KR20160104729A (ko) * 2014-01-24 2016-09-05 컨플루언스 라이프 사이언시스, 인코포레이티드 암 또는 염증성 질환의 치료를 위한 치환 피롤로피리딘 및 피롤로피라진
TN2016000501A1 (en) 2014-05-15 2018-04-04 Iteos Therapeutics Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors.
TW201630907A (zh) * 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
EP3247353A4 (en) 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
JP6775516B2 (ja) 2015-03-17 2020-10-28 ファイザー・インク 新奇な３−インドール置換誘導体、医薬組成物、および使用方法
JP2018527336A (ja) 2015-08-10 2018-09-20 ファイザー・インク ３−インドール置換誘導体、医薬組成物、および使用方法
JP2019512474A (ja) * 2016-03-01 2019-05-16 ノバルティス アーゲー シアノ置換インドール化合物およびｌｓｄ１阻害剤としてのその使用
JP7030066B2 (ja) * 2016-05-26 2022-03-04 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Ｅｇｆｒ阻害剤化合物
EP3523290A4 (en) * 2016-09-30 2020-07-29 Novartis AG IMPROVED EFFICIENCY IMMUNE EFFICIENT CELL THERAPIES
WO2018210658A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018210659A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018210660A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018210661A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2019057660A1 (en) 2017-09-25 2019-03-28 Basf Se INDOLE AND AZAINDOLE COMPOUNDS HAVING 6-CHANNEL SUBSTITUTED ARYL AND HETEROARYL CYCLES AS AGROCHEMICAL FUNGICIDES
EP3730489A1 (en) 2019-04-25 2020-10-28 Basf Se Heteroaryl compounds as agrochemical fungicides
KR102513463B1 (ko) * 2020-11-26 2023-03-29 주식회사 에스앤케이테라퓨틱스 엔도솜 톨-유사 수용체를 제어하는 신규 소분자 화합물 및 이를 이용한 자가면역질환 치료제
CN116332940B (zh) * 2023-02-14 2024-09-13 广西民族大学 一种7-脱氮嘌呤衍生物及其制备方法和应用
WO2024245193A1 (zh) * 2023-05-26 2024-12-05 上海艾力斯医药科技股份有限公司 杂芳环类化合物、其药物组合物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3022A (en) * 1843-03-30 Machine for bending stibrups for paddle-wheels of steam and other
US7004A (en) * 1850-01-08 Connecting ctjttees to shafts of boeing instetjments
US3009A (en) * 1843-03-21 Lard-lamp
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6180643B1 (en) * 1996-11-19 2001-01-30 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
TR200001079T2 (tr) * 1997-10-20 2000-07-21 F.Hoffmann-La Roche Ag Bisiklik kinaz inhibitörleri.
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
JP2001122855A (ja) * 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
JP2004504391A (ja) 2000-07-07 2004-02-12 アンギオジェン・ファーマシューティカルズ・リミテッド 血管新生阻害剤としてのコルキノール誘導体
NZ522861A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
AUPR283801A0 (en) * 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
CA2501947A1 (en) 2002-10-09 2004-04-22 Scios Inc. Azaindole derivatives as inhibitors of p38 kinase
EP2295433A3 (en) 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
PL2332940T3 (pl) * 2004-03-30 2013-03-29 Vertex Pharma Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych
EP2325184A1 (en) 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
AR050365A1 (es) 2004-08-02 2006-10-18 Osi Pharm Inc Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.
WO2006112828A1 (en) 2005-04-15 2006-10-26 Scios, Inc. Azaindole derivatives as inhibitors of p38 kinase
FR2884821B1 (fr) 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
WO2006127587A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
CN102603581B (zh) 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1963320A1 (en) 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
EP1962851A2 (en) 2005-12-22 2008-09-03 SmithKline Beecham Corporation Compounds
JP5140600B2 (ja) 2005-12-23 2013-02-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー オーロラキナーゼのアザインドール阻害薬
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
WO2008014249A2 (en) 2006-07-24 2008-01-31 Sanofi-Aventis Improved preparations of 2 -substituted pyrrolo [2, 3-b] pyrazine ( 4, 7 -diazaindole ) compounds
GB0708141D0 (en) * 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
DE102008052943A1 (de) 2010-04-29
CA2741428A1 (en) 2010-04-29
US20110207732A1 (en) 2011-08-25
EP2342202A1 (de) 2011-07-13
JP5662325B2 (ja) 2015-01-28
ES2559427T3 (es) 2016-02-12
AU2009306795A1 (en) 2010-04-29
EP2342202B1 (de) 2015-11-11
WO2010046013A1 (de) 2010-04-29
AU2009306795B2 (en) 2015-07-16
JP2012506389A (ja) 2012-03-15
CA2741428C (en) 2017-05-09

Similar Documents

Publication Publication Date Title
IL212285A0 (en) Azaindole derivatives
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
ZA201100799B (en) Imidazopyridin-2-one derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
IL211241A0 (en) 7-azaindole derivatives
ZA201100876B (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
ZA201102449B (en) Morpholinopurine derivatives
IL210172A0 (en) Substituted pyrimidin-4-one derivatives
GB0702259D0 (en) 7-azaindole derivatives
IL208336A0 (en) Pyrisazinone derivatives
IL210869A0 (en) Imidazothiadiazoles derivatives
IL216007A0 (en) Isoxazole-pyridine derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
IL211290A0 (en) New 2-amidothiadiazole derivatives
ZA201100948B (en) Acylaminobenzamide derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
IL207192A0 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
IL213424A0 (en) Quinazolinamide derivatives
IL217952A (en) Derivatives of n1- acyl-5-fluoropyrimidinone
IL213927A0 (en) Deoxyactagardine derivatives
IL207191A0 (en) Substituted heteroaylamide oxazepyrimidone derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
IL216761A0 (en) Pyrazinooxazepine derivatives
IL219603A0 (en) Imidazopyridine derivatives